Lilly Aims at Broader Use For Verzenio In Post-Surgery Breast Cancer Setting

 

• Eli Lilly And Co 
  LLY+1.11%+ Free Alerts
   announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for HR-positive, HER2-negative high-risk early breast cancer.
• The new data showed Verzenio’s benefits held up across patient subgroups after longer follow-up.
• In 2020, The monarchE trial hit statistical significance after a median of 15.5 months follow-up. Verzenio’s addition to post-surgery endocrine therapy significantly cut the risk of invasive cancer recurrence or death by 25%, regardless of Ki-67 status. 
• Now, investigators have followed patients for a median of 42 months, coming to the second preplanned interim analysis of patient survival. Nearly all patients had already come off the two-year treatment period.
• In the overall population, the Verzenio group had a 33.6% reduced risk of developing invasive disease recurrence or death over the control arm, which got endocrine therapy alone. 
• Adjuvant Verzenio also reduced the risk of developing the metastatic disease by 34.1%.

https://www.benzinga.com/general/biotech/22/12/29990388/with-additional-data-lilly-aims-broader-use-for-verzenio-in-post-surgery-breast-cancer-setting